| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0016 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate |
2012-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103764127-B |
| titleOfInvention |
The sustained release lipid preconcentrate of pharmacological active substance and the pharmaceutical composition containing it |
| abstract |
The invention discloses sustained release lipid preconcentrate, it is included：A) there is the anhydro sorbitol unsaturated fatty acid ester of the polar head with least two OH (hydroxyl) group；B) phosphatide；And c) there is hydrophobic part, without ionogen the liquid crystal curing agent of 15 to 40 carbon atoms with three acyl groups or carbocyclic ring structure.Lipid preconcentrate exists as liquid phase in no aqueous fluids and liquid crystal is formed in the presence of aqueous fluids.In addition, the invention provides also include the pharmaceutical composition that pharmacologically active principles add preconcentrate. |
| priorityDate |
2011-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |